Bapotulimab Biosimilar - Research Grade

Human

ILDR2

>1mg/ml

IgG2 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q71H61

Blue ice

ICH5372 is a research-grade biosimilar of bapotulimab, supplied as an unconjugated, non-therapeutic analog of the originator molecule for research use only. Bapotulimab (also referred to in the literature as BAY 1905254) is a fully human IgG2 kappa antibody directed against immunoglobulin-like domain containing receptor 2 (ILDR2), a B7-family immune checkpoint. This product is built around the ILDR2 target and reproduces the binding specificity of the parent antibody so that laboratories can study ILDR2 biology, checkpoint blockade, and receptor engagement without sourcing clinical material. It is intended as a consistent, well-characterized reference reagent for in-vitro and functional immunology work, including binding assays, blockade of ILDR2-mediated T-cell suppression, and use as a positive control or benchmark alongside other anti-checkpoint tools. The material is manufactured to research-grade specifications with low endotoxin and is available in bulk milligram to gram quantities suitable for larger studies and screening campaigns. It is not a clinical drug and is not intended for diagnostic or therapeutic use. Investigators should confirm suitability for their specific assay format before use. ILDR2 (immunoglobulin-like domain containing receptor 2; UniProt Q71H61) is a type I transmembrane protein of the B7 family of immunomodulatory receptors. It acts as a negative regulator of T-cell responses, delivering an inhibitory signal that dampens T-cell activation and proliferation. ILDR2 is notably expressed by fibroblastic reticular cells in the T-cell zone of lymph nodes, as well as in immune-privileged and inflamed tissues, positioning it to modulate T-cell priming within the stromal microenvironment. An ILDR2-Fc fusion has shown immunosuppressive activity in preclinical autoimmune models, consistent with its role as a checkpoint. Antibody blockade of ILDR2 relieves this suppression and promotes antigen-specific CD4+ and CD8+ T-cell responses, making ILDR2 an emerging target for cancer immunotherapy. The receptor on activated T cells that ILDR2 engages has not been definitively identified.

Angulin-3, Immunoglobulin-like domain-containing receptor 2, C1orf32

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Bapotulimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Bapotulimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bapotulimab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Bapotulimab that binds ILDR2; for research use only.